Natrol Acquires U.S. Rights to Promensil(R) and Trinovin(R) Brands from Novogen
October 23 2006 - 9:00AM
PR Newswire (US)
CHATSWORTH, Calif. and STAMFORD, Conn., Oct. 23
/PRNewswire-FirstCall/ -- Natrol, Inc. (NASDAQ:NTOL), a premier
manufacturer and distributor of nationally branded nutritional
products, today announced it has licensed the U.S. rights to the
Promensil(R) and Trinovin(R) brands from Novogen Limited
(NASDAQ:NVGN), an Australian-based biotechnology company. The
Promensil and Trinovin brands are dietary supplements based on red
clover isoflavones that are designed to meet specific health needs
of aging adults. Wayne M. Bos, President and CEO of Natrol, stated,
"We are excited about our acquisition of the U.S. rights to
Promensil and Trinovin. This acquisition expands Natrol's product
reach and capabilities with extensive science that will leverage
our promise to provide premium benefits to our customers with
quality and reliability." He added, "We will capitalize on our
strengths in operations, marketing, sales and distribution to build
upon the market presence already established for these brands."
Christopher Naughton, CEO of Novogen, said, "Novogen is extremely
pleased to have secured Natrol as its exclusive licensee for
Promensil and Trinovin in the U.S. Natrol brings marketing
expertise and the product critical mass that will enable the
premium brands Promensil and Trinovin to be elevated to their
potential in the U.S. marketplace." He added, "We believe by
out-licensing our dietary supplement lines in the U.S., Novogen can
focus more resources on bringing its biopharma product offerings
into the marketplace." Promensil is a dietary supplement,
clinically shown to relieve menopausal symptoms, including hot
flashes and night sweats, and maintain bone and heart health.
Promensil currently is distributed through mass and super center,
chain drug and grocery stores, the health food channel, and direct
sale over the Internet. Promensil is sold globally in 12 countries,
including the U.S. Trinovin, which was first sold in the U.S. in
1999, helps maintain prostate and urinary health. Trinovin
currently is distributed through the health food channel and direct
sale over the Internet. About Natrol Founded in 1980, Natrol, Inc.
(NASDAQ:NTOL) is a diversified nutrition company that manufactures
and distributes premium branded nutritional supplements, herbal
teas and sports nutrition products under the Natrol(R), Laci Le
Beau(R) and Prolab(R) brands, respectively. Natrol markets
approximately 50 product categories with more than 500
stock-keeping units (SKU's) designed to meet a wide range of
consumer needs. The products are available at thousands of food,
drug, mass market and independent health food stores, catalogs and
Internet sites, gyms and specialty stores nationally and in select
foreign countries. For more information, visit
http://www.natrol.com/. About Novogen Novogen Limited (NASDAQ:NVGN)
is an Australian biotechnology company which has patented
isoflavone technology for the treatment and prevention of
degenerative diseases and disorders. Over the past ten years,
Novogen has conducted the largest and most comprehensive isoflavone
clinical testing programs in the world. Novogen is involved in drug
discovery and product development for disorders that are commonly
associated with aging and coordinates an international clinical
research and development program with external collaborators,
hospitals and universities. For more information, visit
http://www.novogen.com/. The statements made in this press release
which are not historical facts including statements regarding
expectations for future growth of revenue and profits and trends
concerning net sales, are forward looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
You should be aware that either company's actual results could
differ materially from those contained in the forward-looking
statements, which are based on either company's current
expectations and are subject to a number of risks and
uncertainties, including, but not limited to, adverse trends in the
dietary supplements industry; intense competition; adverse effects
of unfavorable publicity regarding particular products or either
company's industry generally; the risks resulting from either
company's dependence upon, collaboration or contractual
arrangements necessary for the development, manufacture,
commercialization, marketing, sales and distribution of any
products; either company's dependence on the introduction of
successful new products; either company's ability to protect its
patents or proprietary rights and obtain necessary rights to third
party patents and intellectual property to operate its business;
either company's ability to operate its business without infringing
the patents and proprietary rights of others; general economic
conditions; either company's ability to gain market share and shelf
space in each of its distribution channels; either company's
experiencing high rates of product returns; adverse government
regulation; as well as those factors set forth under the heading
"Risk Factors" in Natrol's Annual Report on Form 10-K for the year
ended December 31, 2005 and in either company's other filings with
Securities and Exchange Commission. DATASOURCE: Natrol, Inc.;
Novogen Limited CONTACT: Investor: Teri Lim of Natrol, Inc.,
+1-818-739-6000 Ext. 583, ; or USA: David Sheon, +1-202-518-6321,
or Australia: Christopher Naughton, +612-9878-0088, both for
Novogen Web site: http://www.natrol.com/ http://www.novogen.com/
Copyright
Natrol (NASDAQ:NTOL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Natrol (NASDAQ:NTOL)
Historical Stock Chart
From Jul 2023 to Jul 2024